Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 18, 2018

LivaNova gets US clearance for mitral annuloplasty ring

UK-based medical technology company LivaNova has secured 510(k) clearance from the US Food and Drug Administration (FDA) for its MEMO 4D semi-rigid mitral annuloplasty ring.

UK-based medical technology company LivaNova has secured 510(k) clearance from the US Food and Drug Administration (FDA) for its MEMO 4D semi-rigid mitral annuloplasty ring.

The new device expands the company’s MEMO range and is available in sizes varying from 24mm to 42mm. They are designed to provide more options for patients suffering from mitral regurgitation (MR).

Memo 4D’s large-size rings enable repair even in the case of severe degenerative MR such as Barlow’s disease or enlarged annuli. The improved dimensions are also expected to minimise the risk of systolic anterior motion (SAM).

“Garnering FDA clearance for MEMO 4D addresses a real need and allows a broader patient population suffering from MR to be treated.”

The MEMO 4D device also features ReChord chordal guide system that expedites procedure time and offers a standardised method for implanting neochordae.

In addition, the semi-rigid stability and flexibility of the ring will facilitate natural behaviour, while its gradual saddle design streamlines the physiological geometry in enlarged annuli.

LivaNova North America president Jason Richey said: “LivaNova is committed to innovation for mitral valve repair and replacement technology.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

“Garnering FDA clearance for MEMO 4D addresses a real need and allows a broader patient population suffering from MR to be treated.”

The first implantation of the device has been performed at US-based TriStar Centennial Medical Center by Sreekumar Subramanian, who said that the semi-rigid mitral annuloplasty ring simplifies repair of the degenerative mitral valve, allowing for minimally invasive surgery.

Subramanian further added: “The new larger sizes allow us to treat more patients and pathologies while providing the potential to further improve patient outcomes. With MEMO 4D, surgeons can optimise mitral repair procedures rather than replacing the entire mitral valve.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU